神经生长因子及其受体靶向治疗的研究进展  

Research advances in targeting therapy for human nerve growth factor and its receptor

作　　者：丁洁 金于兰 Ding Jie;Jin Yulan.(No. 1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051 , China)

机构地区：[1]上海生物制品研究所有限责任公司第一研究室,200051

出　　处：《国际生物制品学杂志》2018年第1期40-43,48,共5页International Journal of Biologicals

摘　　要：神经生长因子（nerve growth factor,NGF）是神经营养因子家族成员之一,参与调节神经细胞的生长、发育、分化、生存和损伤后再修复等过程,对中枢及周围神经元功能性表达也有重要调控作用.现有研究充分表明,NGF与其受体的相互作用在疼痛的发生发展过程中起重要作用,针对NGF的靶向单克隆抗体（单抗）疗法有望成为治疗伤害性疼痛和神经性疼痛的新疗法,目前已有相关单抗进入临床试验阶段.此文就靶向NGF单抗的生物学功能以及相关临床研究进展做一综述.Nerve growth factor （NGF）,a member of the neurotrophic factor family,is involved in mediating the growth,development,differentiation,survival,and damage repair of nerve cells.It also plays an important regulation role in the functional expression of central and peripheral neurons.The existing studies have shown that the interaction of NGF with its receptors plays a critical role in the development and progression of pain.Anti-NGF monoclonal antibody therapy is a promising new therapy for nociceptive and neuropathic pain,and related antibodies have entered clinical trial phase.In this paper,the biological function of anti-NGF monoclonal antibody and progress of related clinical studies are reviewed.

关 键 词：神经生长因子 抗体 单克隆 镇痛药 

分 类 号：R741[医药卫生—神经病学与精神病学]